Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study

被引:0
作者
Zheng, Fangchao [1 ,2 ]
Du, Feng [3 ]
Yang, Zixuan [1 ]
Wang, Xue [1 ]
Yue, Jian [1 ]
Ling, Yun [4 ]
Yuan, Peng [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept VIP Med Serv,Canc Hosp, 17 Panjiayuan Nanli, Beijing, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Canc Res Ctr, 17 Panjiayuan Nanli, Jinan 250117, Shandong, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, VIPII Gastrointestinal Canc Div Med Dept, Key Lab Carcinogenesis & Translat Res, Beijing 100021, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Pathol,Canc Hosp, Beijing 100021, Peoples R China
基金
中国国家自然科学基金;
关键词
PATHOLOGICAL COMPLETE RESPONSE; AMERICAN-SOCIETY; GENE AMPLIFICATION; TRASTUZUMAB; THERAPY; GUIDELINE; RECOMMENDATIONS;
D O I
10.1007/s12672-025-02495-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC. Methods 267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed. Results The median follow-up time was 10.3 years (interquartile range: 9.4-10.8 years). HER2/CEP17 ratio of > 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of <= 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unknown, and similarly in the patients who were recorded as not receive trastuzumab (all p > 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, p = 0.02), but there was no difference in OS (p = 0.30) in patients did receive trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive had worse DFS than HER2 normal-positive patients (HR = 3.71; p < 0.01). Conclusion For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict DFS and OS. However, our study supported that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients.
引用
收藏
页数:11
相关论文
共 28 条
[1]   Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Bray, Freddie ;
Laversanne, Mathieu ;
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) :229-263
[2]   STATISTICAL-METHODS FOR CENSORED SURVIVAL-DATA [J].
BRESLOW, N .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1979, 32 (OCT) :181-192
[3]   Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline [J].
Denduluri, Neelima ;
Somerfield, Mark R. ;
Eisen, Andrea ;
Holloway, Jamie N. ;
Hurria, Arti ;
King, Tari A. ;
Lyman, Gary H. ;
Partridge, Ann H. ;
Telli, Melinda L. ;
Trudeau, Maureen E. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) :2416-U186
[4]   High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting [J].
Fuchs, Eva-Maria ;
Koestler, Wolfgang J. ;
Horvat, Reinhard ;
Hudelist, Gernot ;
Kubista, Ernst ;
Attems, Johannes ;
Zielinski, Christoph C. ;
Singer, Christian F. .
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (01) :224-231
[5]   Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC) [J].
Giuliani, Rosa ;
Durbecq, Virginie ;
Di Leo, Angelo ;
Paesmans, Marianne ;
Larsimont, Denis ;
Leroy, Jean-Yves ;
Borms, Marleen ;
Vindeuoghel, Anita ;
Jerusalem, Guy ;
D'Hondt, Veronique ;
Dirix, Luc ;
Canon, Jean-Luc ;
Richard, Vincent ;
Cocquyt, Veronique ;
Majois, Francoise ;
Reginster, Michel ;
Demol, Jan ;
Kains, Jean-Pierre ;
Delree, Paul ;
Keppens, Carine ;
Sotiriou, Christos ;
Piccart, Martine J. ;
Cardoso, Fatima .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) :725-735
[6]  
Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]
[7]   Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio &lt;2.0 and Average HER2 Copy Number ≥4.0 and &lt;6.0 [J].
Hoda, Raza S. ;
Brogi, Edi ;
Xu, Jin ;
Ventura, Katia ;
Ross, Dara S. ;
Dang, Chau ;
Robson, Mark ;
Norton, Larry ;
Morrow, Monica ;
Wen, Hannah Y. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (05) :597-601
[8]   Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab [J].
Kogawa, Takahiro ;
Fujii, Takeo ;
Wu, Jimin ;
Harano, Kenichi ;
Fouad, Tamer M. ;
Liu, Diane D. ;
Shen, Yu ;
Masuda, Hiroko ;
Krishnamurthy, Savitri ;
Chavez-MacGregor, Mariana ;
Lim, Bora ;
Murthy, Rashmi K. ;
Valero, Vicente ;
Tripathy, Debu ;
Ueno, Naoto T. .
ONCOLOGIST, 2020, 25 (06) :E909-E919
[9]   High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predict Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer [J].
Kogawa, Takahiro ;
Fouad, Tamer M. ;
Liu, Diane D. ;
wu, Jimin ;
Shen, Yu ;
Masuda, Hiroko ;
Fujii, Takeo ;
Chavez-MacGregor, Mariana ;
Alvarez, Ricardo H. ;
Hortobagyi, Gabriel N. ;
Valero, Vicente ;
Ueno, Naoto T. .
ONCOLOGIST, 2016, 21 (01) :21-27
[10]   Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata [J].
Lachin, John M. .
STATISTICS IN MEDICINE, 2013, 32 (25) :4413-4425